Showing 2341-2350 of 2527 results for "".
- UK to Test “Subscription-Style” Payment Model in Effort to Spur Development of New Antibioticshttps://modernod.com/news/uk-to-test-subscription-style-payment-model-in-effort-to-spur-development-of-new-antibiotics/2476717/The NHS will test a “subscription-style” payment model for antibiotics as part of efforts by the UK government to incentivise companies to develop new medicines to tackle drug-resistant infections. Under the proposed scheme, the Department of Health and Social Care said Tuesday that d
- Nicox Receives $3 Million Milestone Payment From Eyevance for Zerviate in the UShttps://modernod.com/news/nicox-receives-3-million-milestone-payment-from-eyevance-for-zerviate-in-the-us/2479567/Nicox SA announced that it has received a $3 million milestone payment from partner Eyevance Pharmaceuticals after completion of the regulatory and manufacturing activities. Nicox and Eyevance entered into a licensing agreement for Zerviate in the United States in September 2017 in which N
- Alcon Introduces Air Optix Plus HydraGlyde for Astigmatism Contact Lenseshttps://modernod.com/news/alcon-introduces-air-optix-plus-hydraglyde-for-astigmatism-contact-lenses/2479569/Alcon has launched Air Optix plus HydraGlyde for Astigmatism contact lenses in the United States. The newest addition to Alcon’s contact lens portfolio offers a combination of technologies that support long-lasting lens surface moisture and outstanding comfort to provide astigmatic patients a con
- EyePoint Pharmaceuticals Announces US Commercialization of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercialization-of-dexycu/2479573/EyePoint Pharmaceuticals announced the commercial launch of Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as
- Nicox Signs Agreement for NCX 4251 in China with Ocumension Therapeutics for Up to €12 Millionhttps://modernod.com/news/nicox-signs-agreement-for-ncx-4251-in-china-with-ocumension-therapeutics-for-up-to-e12-million/2476710/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 4251—currently in a phase 2 trial in the United States in patients with acute exacerbations of blepharitis—for a territo
- Ocular Therapeutix Announces Commercial Launch of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-commercial-launch-of-dextenza/2476704/Ocular Therapeutix announced the commercial launch in the United States of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert that enables the delivery of drug
- Low-Cost Retinal Scanner Could Help Prevent Blindness Worldwidehttps://modernod.com/news/low-cost-retinal-scanner-could-help-prevent-blindness-worldwide/2476705/Biomedical engineers at Duke University have developed a low-cost, portable optical coherence tomography (OCT) scanner that promises to bring the vision-saving technology to underserved regions throughout the United States and abroad, according to a university news release. Thanks to a red
- New Research Suggests Glaucoma Screening Could Save Three Million Years Of Blindness In Chinahttps://modernod.com/news/new-research-suggests-glaucoma-screening-could-save-three-million-years-of-blindness-in-china/2476692/New research by Orbis International, Queen’s University Belfast, and Wenzhou Medical University has found that offering glaucoma screening in China could be highly cost-effective while reducing blindness among the population. The novel findings could change
- AbbVie to Buy Allergan in Deal Worth $63 Billionhttps://modernod.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/A blockbuster merger of two large pharma companies will have an impact on the eye care market as AbbVie announced its plans to buy Allergan in a deal worth $63 billion. Under the agreed terms, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share they h
- Alimera’s Iluvien Receives Positive NICE Recommendation for Noninfectious Posterior Uveitishttps://modernod.com/news/alimeras-iluvien-receives-positive-nice-recommendation-for-noninfectious-posterior-uveitis/2476675/Alimera Sciences announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse